GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo therapy offers hope for lymphoma patients who Can't have transplants
Disease control Recruiting nowThis study is for people with a type of blood cancer (large B-cell lymphoma) that has come back or not gotten better after earlier treatments, and who cannot have a stem cell transplant. The trial tests whether adding either tazemetostat or zanubrutinib to a standard two-drug com…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 17, 2026 02:22 UTC
-
Double-Targeted immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for adults with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug cocktail aims to boost standard chemo for aggressive lymphoma
Disease control Recruiting nowThis study tests whether adding a mix of three targeted antibodies (tafasitamab, retifanlimab, and rituximab) before and alongside standard chemotherapy can safely treat people with untreated diffuse large B-cell lymphoma. About 35 adults with this aggressive blood cancer will re…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Can extra drugs boost CAR t success in tough lymphoma?
Disease control Recruiting nowThis study tests whether giving two additional drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy helps control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be rand…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 12, 2026 13:40 UTC